stockrow
Saturday 7 November 2026
Export ALMS’s income statement to Excel — free account
Alumis Inc.
ALMS Healthcare Biotechnology
Alumis Inc.’s revenue for fiscal 2025 (year ended December 2025) was $24.1 million.
- Revenue
- −37.7%
- EPS
- −242.3%
- Free cash flow
- +23.6%
Quarter to June 2026, against a year earlier
6.02
0.17
+2.91%
Follow ALMS
Alert me
| Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|
P/E ratio |
— | — | 0.00 |
Altman Z-Score |
— | — | (1.43) |
P/S ratio |
— | — | 34.51 |
Altman Z″-Score (non-manufacturers) |
— | — | (7.78) |
P/FCF ratio |
— | — | 0.00 |
P/Operating CF |
— | — | (11.54) |
P/B ratio |
— | — | 2.75 |
Price to Tangible BV |
— | — | 3.32 |
EV/Sales |
— | — | 21.68 |
EV/EBITDA |
— | — | 0.00 |
EV/Operating CF |
— | — | (1.41) |
EV/FCF |
— | — | (1.41) |
Quick Ratio |
2.35 | 5.66 | 4.21 |
Current Ratio |
2.56 | 6.01 | 4.34 |
Net Debt/EBITDA |
0.31 | 0.97 | 0.69 |
Debt/Assets |
0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 |
Asset Turnover |
— | 0.00 | 0.06 |
Operating CF/Net income |
0.84 | 0.87 | 1.52 |
Capex/Depreciation |
(3.50) | (0.55) | (0.19) |
| 0.00% | 743.43% | (86.68%) | |
| 0.00% | (136.66%) | (64.63%) | |
ROIC |
0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(282.18%) | (106.51%) | (92.48%) |
Average Days of Receivables |
— | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 1,604.98% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 381.94% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.12 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 180.97% |
Graham Net Nets |
— | — | 0.25 |
Graham Number |
— | — | 0.00 |
Earnings Yield |
— | — | (30.56%) |
Free Cash Flow Yield |
— | — | (44.61%) |
Revenue per Share |
0.00 | 0.00 | 0.28 |
Operating CF per Share |
(60.45) | (9.00) | (4.35) |
Capex per Share |
(2.09) | (0.06) | (0.01) |
Free Cash Flow per Share |
(62.54) | (9.06) | (4.35) |
Cash per Share |
22.82 | 10.17 | 3.63 |
Shareholders Equity per Share |
(157.78) | 9.18 | 3.54 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 |
Book value per Share |
(157.78) | 9.18 | 3.54 |
Free Cash Flow |
(134.47) | (256.81) | (370.18) |
Working Capital |
32.49 | 255.28 | 244.91 |
Capital Expenditures |
(4.50) | (1.73) | (0.65) |
Net Current Asset Value |
(375.51) | 225.30 | 207.59 |
EV/EBIT |
— | — | 0.00 |
Capex to Sales |
0.00 | 0.00 | 0.03 |
Price to Operating Income |
— | — | 0.00 |
| Other line items | |||
Depreciation/Fixed assets |
0.06 | 0.15 | 0.19 |
Cash ROIC |
46.34% | (46.83%) | (60.70%) |
Accounts Receivable Turnover |
— | — | 0.00 |
Accounts Payable Turnover |
— | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 |
Average Payables |
— | 5.37 | 9.87 |
Average Assets |
— | 215.30 | 376.47 |
Average Common Equity |
— | (39.58) | 280.70 |
Columns are period end dates · fundamentals updated 26 Oct 2026